Sam Brusco, Associate Editor07.26.22
Exo, a health information and medical device company will acquire Medo, a Canadian artificial intelligence (AI) tech developer. Exo aims to integrate Medo’s Sweep AI into its ultrasound platform to make ultrasound more accessible.
Medo’s ultrasound tech lowers the expertise needed to diagnose common and critical conditions via automated image acquisition and interpretation. The company has two FDA-cleared algorithms with more in development, as well as a library of millions of ultrasound images and longitudinal health data.
These specialties bring the opportunity for speedier point-of-care ultrasound adoption. Medo also has partnership with top healthcare institutions in Asia and Canada to facilitate global clinical validation and adoption.
“This acquisition is about bringing unprecedented ease of use to ultrasound imaging—allowing caregivers to easily obtain and interpret ultrasound images,” Sandeep Akkaraju, CEO and founder of Exo told the press. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software. We are excited about joining forces with an innovative team that shares our vision of taking medical imaging everywhere.”
"Exo’s powerful hardware and workflow technologies and Medo’s AI will dramatically reduce the challenges that have long held back the widespread adoption of point-of-care ultrasound," added Dornoosh Zonoobi, CEO of Medo. “The ease of imaging and immediacy of diagnostic information we provide will radically transform medical care, creating a world where caregivers can image the body as easily as snapping a photo on a smartphone.”
Exo also recently rolled out Exo Works, a point-of-care workflow solution to streamline documentation, billing, and quality assurance from one platform. The company will be commercializing a handheld ultrasound device that uses new tech for powerful imaging at a fraction of a cart system’s cost.
Medo’s ultrasound tech lowers the expertise needed to diagnose common and critical conditions via automated image acquisition and interpretation. The company has two FDA-cleared algorithms with more in development, as well as a library of millions of ultrasound images and longitudinal health data.
These specialties bring the opportunity for speedier point-of-care ultrasound adoption. Medo also has partnership with top healthcare institutions in Asia and Canada to facilitate global clinical validation and adoption.
“This acquisition is about bringing unprecedented ease of use to ultrasound imaging—allowing caregivers to easily obtain and interpret ultrasound images,” Sandeep Akkaraju, CEO and founder of Exo told the press. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software. We are excited about joining forces with an innovative team that shares our vision of taking medical imaging everywhere.”
"Exo’s powerful hardware and workflow technologies and Medo’s AI will dramatically reduce the challenges that have long held back the widespread adoption of point-of-care ultrasound," added Dornoosh Zonoobi, CEO of Medo. “The ease of imaging and immediacy of diagnostic information we provide will radically transform medical care, creating a world where caregivers can image the body as easily as snapping a photo on a smartphone.”
Exo also recently rolled out Exo Works, a point-of-care workflow solution to streamline documentation, billing, and quality assurance from one platform. The company will be commercializing a handheld ultrasound device that uses new tech for powerful imaging at a fraction of a cart system’s cost.